


Amendments to the Claims:

1. (Currently Amended) A compound of formula (I)



R is halogen, C₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy;

R₁ is hydrogen, halogen, C₃₋₇cycloalkyl, hydroxy, nitro, cyano or C₁₋₄ alkyl optionally substituted by halogen, cyano or C₁₋₄ alkoxy;

R₂ is hydrogen or C₁₋₄ alkyl;

R₃ and R₄ independently are hydrogen, cyano, C₁₋₄ alkyl or R₃ together with R₄ and the carbon to which they are bonded form a C₃₋₇ cycloalkyl;

R₅ is trifluoromethyl, S(O)_t C₁₋₄ alkyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy, halogen or cyano;

R₆ is hydrogen or (CH₂)_rR₇;

R₇ is hydrogen, C₃₋₇ cycloalkyl, NH(C₁₋₄alkylOC₁₋₄alkoxy), NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, OC(O)NR₉R₈, NR₈C(O)[[5]]R₉ or C(O)NR₉R₈;

R₉ and R₈ independently are hydrogen, C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

m is zero or an integer from 1 to 4;

n is 1;

p is zero or an integer from 1 to 3;

q is an integer from 1 to 3;

r is an integer from 1 to 4;

t is 0, 1 or 2 ;

~~provided that when m is 0, p is 2, q, r and n is 1, R₁, R₂, R₃, R₄, R₅ and R₇ are hydrogen and R is chlorine, then R₅ is not iodine;~~
or a pharmaceutically acceptable salt or solvate thereof.

2. (Previously presented) A compound as claimed in claim 1 wherein R is halogen, cyano, trifluoromethyl or a C₁₋₄ alkyl and p is 0 or an integer from 1 to 2.
3. (Previously presented) A compound as claimed in claim 1 wherein R₅ is trifluoromethyl, cyano, methyl or halogen and q is an integer from 1 to 2.
4. (Currently Amended) A compound as claimed in claim 1 wherein R₆ is hydrogen or (CH₂)_rR₇ in which r is 1 or 2 and R₇ is hydrogen, cyclopropyl, C(O)N(C₁₋₄ alkyl)₂, or C(O)NH(C₁₋₄ alkyl) or ~~C₁₋₄ alkoxy~~.
5. (Currently Amended) A compound as claimed in claim 1 wherein R is C₁₋₄ alkyl, halogen, trifluoromethyl or cyano; R₁ is hydrogen, methyl, ethyl or halogen, R₂ is a methyl or hydrogen, R₃ and R₄ are independently hydrogen or methyl, R₅ is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine, R₆ is hydrogen, methyl, ethyl methylcyclopropyl (CH₂)₂OCH₃ or CH₂C(O)N(CH₃)₂, p is 0 or an integer from 1 to 2, m is 0 or 1, n is 1, and q is 1 or 2.
6. (Cancelled).
7. (Previously presented) A compound selected from:
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;
4-(4-Fluorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-
methylamide;
4-(4-Chlorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-
methylamide;
4-(4-Fluorophenyl)-piperidine-4-carboxylic acid (3,5-dichloro-benzyl)-methylamide;
N-(3,5-Bis-trifluoromethyl)-benzyl-2-[(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-
acetamide;
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-
acetamide;
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluorophenyl)-azepin-4-yl]-N-methyl-acetamide;
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-
acetamide;
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5- Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-[2-(methoxy)ethyl]-4-piperidinyl]-*N*-methylacetamide;

N-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]acetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]acetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-(2-methylphenyl)-4-piperidinyl]acetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-(2-methylphenyl)-4-piperidinyl]acetamide;

N-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-*N*-methylacetamide ;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide;

2-[1-(Cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;

2-[4-{2-[[3,5-Dibromophenyl)methyl](methyl)amino]-2-oxoethyl}-4-(4-fluorophenyl)-1-piperidinyl]-*N,N*-dimethylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[1-ethyl-4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]acetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]acetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-dimethylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide ;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;


N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-1-methyl-4-piperidiny]-N-[1-(3,5-dibromophenyl)ethyl]-N-methylacetamide;
2-[4-(3-Chlorophenyl)-4-piperidiny]-N-[1-(3,5-dichlorophenyl)ethyl]-N-methylacetamide;
2-[4-(3-Chlorophenyl)-1-methyl-4-piperidiny]-N-[1-(3,5-dichlorophenyl)ethyl]-N-methylacetamide;
2-[4-(3-Chlorophenyl)-4-piperidiny]-N-[(3,5-dibromophenyl)methyl]-N-methylacetamide;
N-[1-(3,5-Dichlorophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidiny]-N-methylacetamide;
N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidiny]-N-methylacetamide;
N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidiny]-N-methylacetamide ;
N-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-4-piperidiny]-N-methylacetamide;
N-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidiny]-N-methylacetamide;
N-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-4-piperidiny]-N-methylacetamide;
N-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidiny]-N-methylacetamide;
2-[4-(4-Cyanophenyl)-4-piperidiny]-N-[1-(3,5-dibromophenyl)ethyl]-N-methylacetamide;
diastereoisomers or enantiomers thereof and pharmaceutically acceptable salts thereof.

8 (Previously presented) A compound selected from
[N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide (enantiomer 1);
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(1-methyl-4-phenyl-piperidin-4-yl)-N-methyl-acetamide (enantiomer 1);
N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide (enantiomer 1);
and pharmaceutically acceptable salts thereof.

9. (Previously presented) A process (A) for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R_6 is a nitrogen protecting group or $(CH_2)_nR_7$, with amine (III)



wherein R_2 is hydrogen, C_{1-4} alkyl or a nitrogen protecting group, followed where necessary by removal of any nitrogen protecting group.

10-12. (Canceled)


13. (Previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.

14. (Canceled)

15. (Previously presented) A compound as claimed in claim 1 wherein R is fluorine or chlorine, cyano, trifluoromethyl or methyl and p is 0 or an integer from 1 to 2.

16. (Currently Amended) A compound as claimed in claim 1 wherein R is C_{1-4} alkyl, chlorine or fluorine, trifluoromethyl or cyano; R_1 is hydrogen, methyl, ethyl or fluorine, R_2 is a methyl or hydrogen, R_3 and R_4 are independently hydrogen or methyl, R_5 is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine, R_6 is hydrogen, methyl, ethyl methylcyclopropyl $(CH_2)_2OCH_3$ or $CH_2C(O)N(CH_3)_2$, p is 0 or an integer from 1 to 2, m is 0 or 1, n is 1, and q is 1 or 2.

17. (Previously presented) A process (B) for the preparation of a compound as claimed in claim 1 wherein R_2 is C_{1-4} alkyl comprising reacting a compound of formula (Ia), with $(C_{1-4} \text{ alkyl})L$ wherein L is a suitable leaving group selected from iodine, bromine



18. (Withdrawn) A method for the treatment of a condition mediated by a tachykinin and/or selective inhibition of serotonin reuptake transporter protein in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
19. (Withdrawn) The method as claimed in claim 18, wherein said tachykinin is substance P.
20. (Withdrawn) The method as claimed in claim 18, wherein said mammal is man.